DOCSLIB.ORG

Page 1 Consgrpdesc Itemno Unit 1003 VIAL 1005 AM/VI 1010 BOT 1020 BOT 1021 BOT 1022 BOT 1023 BOT 1024 BOT

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

consgrpdesc Itemno Description Unit ANTACIDS (HYPERACIDITY, REFLUX, 1003 PANTOPRAZOLE INJ 40MG VIAL VIAL ULCERS) ANTACIDS (HYPERACIDITY, REFLUX, 1005 RANITIDINE HCL 50MG/ INJ AMP/VIAL AM/VI ULCERS) ANTACIDS (HYPERACIDITY, REFLUX, 1010 ALUMINIUM HYDROXIDE (DRIED) 610 MG PER 10 ML 200 ML BOT ULCERS) BOTTLE ANTACIDS (HYPERACIDITY, REFLUX, 1020 ANTACID LIQUID CONTAINING ALUMINIUM SALT +MAGNESIUM SALT BOT ULCERS) WITH AANTIFOAMING AGENT 170ML ANTACIDS (HYPERACIDITY, REFLUX, 1021 ANTACID LIQUID CONTAINING DRIED ALUMINIUM HYDROXID E GEL, BOT ULCERS) MAGNESIUM HYDROXIDE WITH OR WITHOUT METHYL POLYSILOXANE, 450ML BOTTLE ANTACIDS (HYPERACIDITY, REFLUX, 1022 ANTACID LIQUID CONTAINING ALUMIUM SALT AND MAGNESIUM SALT BOT ULCERS) 170ML ANTACIDS (HYPERACIDITY, REFLUX, 1023 SUCRALFATE SUSPENSION 1GM/10ML 200MLBOTTLE BOT ULCERS) ANTACIDS (HYPERACIDITY, REFLUX, 1024 ANTACID LIQUID 200ML,EACH 5ML CONTAINS OXETACAINE B.P BOT ULCERS) 10MG,ALUMINIUM HYDROXIDE 0.291G& MAGNESIUM HYDROXIDE IP 98MG ANTACIDS (HYPERACIDITY, REFLUX, 1025 TAB ESOMEPRAZOLE 40MG TAB ULCERS) ANTACIDS (HYPERACIDITY, REFLUX, 1026 ESOMEPRAZOLE SODIUM 40MG IV VIAL VIAL ULCERS) Page 1 ANTACIDS (HYPERACIDITY, REFLUX, 1030 ANTACID CONTAINING ALUMINIUM AND MAGNESIUM TAB ULCERS) SALT/MAGALDRATE, WITH ANTI-FOAMING AGENT TABLET ANTACIDS (HYPERACIDITY, REFLUX, 1031 TAB ANTACID CONTAINING ALUMINIUM AND MAGNESIUM SALT WITH TAB ULCERS) ANTIFOAMING AGENT IN CHEWABLE FORM ANTACIDS (HYPERACIDITY, REFLUX, 1032 SIMETHICONE 125MG + METOCLOPRAMIDE 5MG TAB TAB ULCERS) ANTACIDS (HYPERACIDITY, REFLUX, 1040 FAMOTIDINE 20MG TAB TAB ULCERS) ANTACIDS (HYPERACIDITY, REFLUX, 1041 FAMOTIDINE 40MG TAB TAB ULCERS) ANTACIDS (HYPERACIDITY, REFLUX, 1045 LANSOPRAZOLE 30MG CAP CAP ULCERS) ANTACIDS (HYPERACIDITY, REFLUX, 1046 LANSOPRAZOLE 15MG TAB TAB ULCERS) ANTACIDS (HYPERACIDITY, REFLUX, 1047 RABEPRAZOLE 20 MG TABLET TAB ULCERS) ANTACIDS (HYPERACIDITY, REFLUX, 1050 RANITIDINE 150MG TAB TAB ULCERS) ANTACIDS (HYPERACIDITY, REFLUX, 1051 RANITIDINE 300MG TAB TAB ULCERS) ANTACIDS (HYPERACIDITY, REFLUX, 1060 ROXATIDINE ACETATE HYDROCHLORIDE 75MG TAB TAB ULCERS) ANTACIDS (HYPERACIDITY, REFLUX, 1070 OMEPRAZOLE 20MG CAP CAP ULCERS) Page 2 ANTACIDS (HYPERACIDITY, REFLUX, 1071 OMEPRAZOLE10MG CAP CAP ULCERS) ANTACIDS (HYPERACIDITY, REFLUX, 1075 EACH PACK CONTAINS OMEPRAZOLE CAP 20MG,TINIDAZOLE TAB PACK ULCERS) 500MG,AMOXYCILLIN TAB 750MG ANTACIDS (HYPERACIDITY, REFLUX, 1100 PANTOPRAZOLE 40MG TAB TAB ULCERS) ANTACIDS (HYPERACIDITY, REFLUX, 1105 RABEPRAZOLE 20MG + DOMPERIDONE 30MG SUSTAINED RELEASE CAP ULCERS) CAP ANTACIDS (HYPERACIDITY, REFLUX, 1200 SUCRALFATE 1 GM TAB TAB ULCERS) ANTIDIARROHEALS 2005 PREBIOTIC AND PROBIOTIC CONTAINING STREPTOCOCCUS CAP FAECALIS,CLOSTRIDIUM BUTYRICUM,BACILLUS MESENTRICUS AND LACTIC ACID BACILLUS CAP - PLAIN ANTIDIARROHEALS 2006 LACTIC ACID BACILLUS NOT LESS THAN 60 MILLIONS SPORES TAB ANTIDIARROHEALS 2007 LACTIC ACID BACILLUS NOT LESS THAN 150 MILLIONS SPORES SACHE CONTAINS IN 1.8 G POWDER ANTIDIARROHEALS 2008 PREBIOTIC AND PROBIOTIC CONTAINING STREPTOCOCCUS CAP FAECALIS 60 MILLION,CLOSTRIDIUM BUTYRICUM 4 MILLION,BACILLUS MESENTRICUS 2 MILLION AND LACTIC ACID BACILLUS 100 MILLION CAP DS ANTIDIARROHEALS 2009 SACHET 0.5G CONTAINS STREPTOCOCCUS FAECALIS T-110 JPC 30 SACHE MILLION,CLOSTRIDIUM BUTYRICUM TO-A 2 MILLION,BACILLUS MESENTERICUS TO-A JPC 1MILLION,LACTIC ACID BACILLUS 50MILLION(LACTOBACILLUS SPOROGENES) Page 3 ANTIDIARROHEALS 2010 LOPERAMIDE 2MG TAB TAB ANTIDIARROHEALS 2011 RACEZODOTRIL 100MG TAB TAB ANTIDIARROHEALS 2020 METRONIDAZOLE 200MG/5ML 60ML BOT BOT ANTIDIARROHEALS 2021 METRONIDAZOLE 200MG TAB TAB ANTIDIARROHEALS 2022 METRONIDAZOLE 400MG TAB TAB ANTIDIARROHEALS 2030 SECNIDAZOLE 1GM TAB TAB ANTIDIARROHEALS 2048 TAB.TINIDAZOLE 300MG TAB ANTIDIARROHEALS 2049 TINIDAZOLE 500MG TAB TAB ANTIDIARROHEALS 2050 TINIDAZOLE 1GM TAB TAB ANTIDIARROHEALS 2055 TAB.METRONIDAZOLE 300MG/400MG+FURAZOLIDONE 100MG TAB ANTIDIARROHEALS 2056 TAB.DILOXANIDE FUROATE 250MG,METRONIDAZOLE 200MG TAB ANTIDIARROHEALS 2057 TAB.LOPERAMIDE 2MG TAB Page 4 ANTIDIARROHEALS 2060 ENTERO GERMINA -BACILLUS CLAUSIC 2 BILLION SPORES 5ML VIAL- VIAL ANTIDIARROHEALS 2100 SACCHAROMYCES BOULARDII 100MG CAP CAP DRUGS ACTING COLON & RECTUM 3010 HYDROCORTISONE ACETATE, FRAMYCETIN & SODIUM HEPARINATE TUBE OINT 10G TUBE (LIKE PROCTOSEDYL) DRUGS ACTING COLON & RECTUM 3011 BECLOMETHASONE WITH PHENYLEPHRINE AND LIGNOCAINE OINT TUBE FOR PILES 20 G DRUGS ACTING COLON & RECTUM 3015 5-AMINE SALICYLIC ACID 400G/60 ML ENEMA(MESALAZINE) PKT DRUGS ACTING COLON & RECTUM 3016 TAB.5 AMINO SALICYLIC ACID 250MG TAB DRUGS ACTING COLON & RECTUM 3017 5-AMINO SALICYLIC ACID 400MG TAB TAB DRUGS ACTING COLON & RECTUM 3018 BALSALAZIDE DISODIUM DIHYDRATE 750MG TAB DRUGS ACTING COLON & RECTUM 3020 SULPHASALAZINE 500MG TAB TAB DRUGS ACTING COLON & RECTUM 3300 HYDROCORTISONE ACETATE 10% W/W RECTAL FOAM CANN DRUGS ACTING COLON & RECTUM 3510 MESALAMINE PELLETS U.S.P 500 MG SACHE ENZYMES/HEPATOBILIARY DRUGS 4010 ENZYMES ALONG WITH ANTIFLATULENTS TAB/CAP CAP Page 5 ENZYMES/HEPATOBILIARY DRUGS 4015 DL METHIONINE CHOLINE AND VITAMINS TAB TAB ENZYMES/HEPATO-BILARY DRUG ENZYMES/HEPATOBILIARY DRUGS 4018 PANCREATIN TAB CONTAINING MINIMUM 125 MG TAB ENZYMES/HEPATOBILIARY DRUGS 4019 PANCREATIN 125MG EQUIVALENT TO LIPASE 10000 UNITS AMYLASE TAB 9000UNITS PROTEASE 500UNITS ENZYMES/HEPATOBILIARY DRUGS 4020 PANCREATIN TAB CONTAINING AMYLASE,PROTEASE AND MINIMUM TAB 10000 UNITS OF LIPASE- MINIMICROSPHERE ENZYMES/HEPATOBILIARY DRUGS 4030 URSODEOXYCHOLIC ACID 150MG TAB TAB ENZYMES/HEPATOBILIARY DRUGS 4600 L-ORNITHINE-L-ASPARTATE LA 5G/10ML INJ. AMP ENZYMES/HEPATOBILIARY DRUGS 4601 EACH ENTERIC-COATED TAB CONTAINS L-ORNITHINE-L-ASPARTATE TAB 150MG & PANCREATIN IP 100MG ENZYMES/HEPATOBILIARY DRUGS 4602 S-ADENOSYL METHIONINE - ADEMETIONINE TAB LETS - 400MG (SAM) TAB ENZYMES/HEPATOBILIARY DRUGS 4605 TAB. RIFAXIMIN 200MG TAB ENZYMES/HEPATOBILIARY DRUGS 4606 RIFAXIMIN 400MG TAB TAB GI SEDATIVES, ANTISPASMODICS & 5010 HYOSCINE BUTYL BROMIDE 20MG/ML INJ AMP PROKINETICS Page 6 GI SEDATIVES, ANTISPASMODICS & 5015 DICYCLOMINE HCL DROPS 100MG/ML, 10ML BOTTLE BOT PROKINETICS GI SEDATIVES, ANTISPASMODICS & 5016 INJ,DICYCLONINE HCL 10MG/ML 2ML AMP AMP PROKINETICS GI SEDATIVES, ANTISPASMODICS & 5020 CISAPRIDE 10MG TAB TAB PROKINETICS GI SEDATIVES, ANTISPASMODICS & 5025 DICYCLOMINE HCL 10MG/20 MG WITH PARACETAMOL 500MG TAB PROKINETICS GI SEDATIVES, ANTISPASMODICS & 5030 MEBEVERINE HCL 135MG TAB TAB PROKINETICS GI SEDATIVES, ANTISPASMODICS & 5035 MOSAPRIDE 5MG TAB TAB PROKINETICS GI SEDATIVES, ANTISPASMODICS & 5040 OXYPHENONIUM TAB 10MG TAB PROKINETICS GI SEDATIVES, ANTISPASMODICS & 5041 METOCLOPRAMIDE HYDROCHLORIDE 5MG PER 5ML SYP BOT PROKINETICS BOTTLE GI SEDATIVES, ANTISPASMODICS & 5045 LEVOSULPIRIDE 12.5MG/ML 2ML INJ AMP PROKINETICS GI SEDATIVES, ANTISPASMODICS & 5050 ITOPRIDE 50 MG TABLET TAB PROKINETICS LAXATIVES 6010 TAB BISACODYL 5MG TAB LAXATIVES 6015 BISACODYL SUPPOSITORIES IP 10MG FOR ADULT NO Page 7 LAXATIVES 6020 LAXATIVE-BULKFORMING LAXATIVE CONTAINING ISAPGOL HUSK OR TIN PSYLLIUM LAXATIVES 6025 EACH 15ML CONTAINS LIQUID PARAFFIN I.P 3.75ML,MILK OF BOT MAGNESIA I.P 11.25ML,COLOUR-CARMOISINE & PONCEAU 4R 170ML LAXATIVES 6030 LACTULOSE SYP 10G/15ML 200ML BOTTLE BOT LAXATIVES 6035 LACTULOSE ENEMA 20% W/V 250ML PACK PACK LAXATIVES 6040 POLY ETHYLENE GLYCOL 118GM WITH ELECTROLYTES PER SACHE SACHET-POWDER FOR ORAL USE (LIKE PEGLEC) LAXATIVES 6045 SACHET CONTAINS POLYETHYLENE GLYCOL, ACTIVATED SACHE DIMETHICONE WITH ELECTROLYTES FOR ORAL SOLN LAXATIVES 6046 MONOBASIC SODIUM PHOSPHATE DIHYDRATE 24.417G,DISODIUM PACK HYDROGEN PHOSPHATE DIHYDRATE 5.439G AND SODIUM BENZOATE AS PRESERVATIVE PER 45ML PACK. (EXELYTE OR SIMILAR 2X45ML PACK) LAXATIVES 6050 SODIUM PHOSPHATE ENEMA POUCH 100ML POUCH LAXATIVES 6060 XINBAOSHEN 300MG TAB CHINESE HERBAL TAB LAXATIVE ALLERGIC DISORDERS 9005 PHENIRAMINE MALEATE 22.75MG/ML INJ 2ML AMP (INJ.AVIL) AMP ALLERGIC DISORDERS 9006 INJ. AVIL 10ML VIAL Page 8 ALLERGIC DISORDERS 9015 ASTEMIZOLE 10MG TAB TAB ALLERGIC DISORDERS 9020 AZATADINE MALEATE 1MG TAB TAB ALLERGIC DISORDERS 9025 EBASTINE 10 MG TABLET TAB ALLERGIC DISORDERS 9030 CETRIZINE DIHYDROCHLORIDE 5MG/5ML SYRUP BOT ALLERGIC DISORDERS 9031 CETIRIZINE HYDROCHLORIDE 10MG TAB TAB ALLERGIC DISORDERS 9033 LEVOCETRIZINE DIHYDROCHLORIDE 5MG TAB TAB ALLERGIC DISORDERS 9035 LORATIDINE 10MG TAB TAB ALLERGIC DISORDERS 9040 CHLORPHENIRAMINE MALEATE 4MG TAB TAB ALLERGIC DISORDERS 9060 EMBRAMINE 25MG TAB TAB ALLERGIC DISORDERS 9070 FEXOFENADINE 120MG TAB CAP ALLERGIC DISORDERS 9071 FEXOFENADINE 180MG TAB TAB ALLERGIC DISORDERS 9072 DIPHENHYDRAMINE HYDROCHORIDE 25MG CAP CAP Page 9 ALLERGIC DISORDERS 9080 KETOTIFEN 1MG TAB TAB ALLERGIC DISORDERS 9081 KETOTIFEN SYRUP 60ML (1MG/5ML) BOT ALLERGIC DISORDERS 9091 PHENIRAMINE MALEATE 15MG/5ML SYP 100ML BOT ALLERGIC DISORDERS 9092 PHENIRAMINE MALEATE 25MG TAB TAB ALLERGIC DISORDERS 9093 PARACETAMOL 500 MG WITH ANTIHISTAMINE AND DECONGESANT TAB ALLERGIC DISORDERS 9094 CAFFEINE CITRATE ORAL SOLUTION - 20MG/ML BOT ALLERGIC DISORDERS 9095 CAFFEINE CITRATE ORAL SOLUTION - 20MG/ML 1.5ML BOT ALLERGIC DISORDERS 9096 CAFFEINE CITRATE INJ 20MG/ML 3ML VIAL VIAL ALLERGIC DISORDERS 9100 TERFENADINE 60MG TAB TAB ANTI-ANGINALS 10030 NITROGLYCERINE 5MG/ML 5ML AMP AMP ANTI-ANGINALS 10035 INJ.PROSTAGLANDIN 500MCG / 1ML AMP AMP ANTI-ANGINALS 10040 GLYCERYL TRINITRATE 2.6MG/2.5 MG TAB TAB Page 10 ANTI-ANGINALS 10045 NITROCONTIN 6.5MG TR CAP [GLYCERYL TRINITRATE 6.4MG/6.5MG CAP TR CAP] ANTI-ANGINALS 10050 NITROGLYCERINE TRANSDERMAL 5MG PATCHES NO ANTI-ANGINALS 10060 ISOSORBIDE DINITRATE 5MG TAB
Recommended publications
  • 30 Day Change Notice Effective Date

    30 Day Change Notice Effective Date

    30 Day Change Notice Effective Date: January 1st, 2021 NEW PREFERRED DRUGS THERAPEUTIC CLASS NO PA REQUIRED PREFERRED Central Nervous System (CNS) Agents: Anticonvulsants Clobazam (Generic of Onfi) Central Nervous System (CNS) Agents: Multiple Aubagio EndocrineSclerosis Agents: Osteoporosis-Bone Ossification Forteo Enhancers Gastrointestinal Agents: Anti-Emetics Bonjesta Genitourinary Agents: Benign Prostatic Hyperplasia Alfuzosin (Generic of Uroxatral) Dutasteride (Generic of Avodart) Genitourinary Agents: Electrolyte Depleter Agents Sevelamer (Generic of Renagel and Renvela) Infectious Disease Agents: Antibiotics-Macrolides Eryped Infectious Disease Agents: Antivirals-HIV Atazanavir Sulfate Oral Powder (Generic of Reyataz) Tivicay PD Infectious Disease Agents: Antibiotics-Tetracyclines Vibramycin Suspension (no PA Required for age 12 or under) Ophthalmic Agents: Antibiotics and Antibiotic -Steroid Neomycin/Polymyxin/Bacitracin/Hydrocortisone Ointment Combination Drops and Ointments Ophthalmic Agents: Glaucoma Agents Dorzolamide/Timolol (Generic of Cosopt PF) NEW CLINICAL PA REQUIRED “PREFERRED” DRUGS THERAPEUTIC CLASS CLINICAL PA REQUIRED PREFERRED Blood Formation, Coagulation, and Thrombosis Agents: Corifact Hemophilia Factors Immunomodulator Agents for Systemic Inflammatory Taltz Disease Immunomodulator Agents for Systemic Inflammatory Xeljanz 5mg Disease NEW STEP THERAPY REQUIRED “PREFERRED” THERAPEUTIC CLASS STEP THERAPY REQUIRED “PREFERRED” Central nervous System (CNS) Agents: Anti-Migraine, Aimovig Prophylaxis Treatment Ajovy
  • Active Pharmaceutical Ingredients

    Active Pharmaceutical Ingredients

    Active Pharmaceutical Ingredients Catalog HPD-5E ® CREATING A HEALTHY WORLDTM Active Pharmaceutical Ingredients (APIs) Available for International Markets Human Pharmaceutical Department www.Pharmapex.net Catalog HPD-5E *Not all products referred to on this site are available in all countries and our products are subject to different regulatory requirements depending on the country of use. Consequently, certain sections of this site may be indicated as being intended only for users in specic countries. Some of the products may also be marketed under different trade names. You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence. For inquiries about the availability of any specic product in your country, you may simply contact us at [email protected]. **Products currently covered by valid US Patents may be offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk. ©2016, Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved. Toll-Free: 1.844.PHARMAPEX Fax: + 1.619.881.0035 ACTIVE PHARMACEUTICAL [email protected] CREATING A HEALTHY WORLD™ www.Pharmapex.net INGREDIENTS About Pharmapex’s Human Pharmaceuticals Department: Pharmapex’s Human Pharmaceuticals Department (HPD) is a leading source for high-quality Active Pharmaceutical Ingredients (APIs) and Finished Pharmaceutical Products (FPPs) in various markets across the globe. With an extensive product portfolio, our consortium of companies is dedicated to addressing and solving the most important medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes).
  • Tanibirumab (CUI C3490677) Add to Cart

    Tanibirumab (CUI C3490677) Add to Cart

    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
  • Anatomy and Physiology of Peritoneal Dialysis

    Anatomy and Physiology of Peritoneal Dialysis

    Anatomy and Physiology of Peritoneal Dialysis Isaac Teitelbaum, MD Professor of Medicine Director, Acute & Home Dialysis Programs University of Colorado Hospital Denver, Colorado •1 Outline • Peritoneal cavity as a dialysis system • Models of peritoneal transport • Physiology of peritoneal transport Inverse relationship between solute transport and ultrafiltration • Kinetics of peritoneal transport • Synthesis & Application • Middle Molecules Anatomy of The Peritoneum • The lining of the abdominal cavity • Two layers: parietal - lines the anterior wall and undersurface of the diaphragm - 20% of total SA; blood supply from abdominal wall visceral - covers the abdominal organs - 80% of total SA; blood supply from mesenteric aa and portal vv Gokal R, Textbook of PD, pp. 61-70 •3 Anatomy of The Peritoneum • Size 1.5 – 2 m2; approximates BSA • Highly Vascular • Semi-permeable/bi-directional • “Lymphatic” drainage through diaphragmatic stomata • Continuous with Fallopian Tubes in females Gokal R, Textbook of PD, pp. 61-70 1. The two main properties of the peritoneal membrane are: a. Semi permeable – this allows substances of certain sizes to move from an area of greater concentration to less concentration. b. Bi Directional - substances move in either direction across the membrane. 2. So-called “lymphatic” drainage refers to bulk flow from the peritoneal cavity back to the circulation. This actually occurs across tissues as well as lymphatics. As this is convective flow, dissolved solutes move with the fluid. Thus, fluid reabsorption results in loss of solute clearance as well as loss of fluid removal. 3. It is important to be aware of the continuity of the peritoneal cavity with the Fallopian tubes as retrograde menstruation- which may occur in any woman but goes undetected- will cause bloody dialysate and create concern in the PD patient.
  • INTEGRIS Formulary July 2017

    INTEGRIS Formulary July 2017

    INTEGRIS Formulary July 2017 Foreword FORMULARY EXCLUDED THERAPEUTIC DRUG This document represents the efforts of the MedImpact Healthcare Systems THERAPEUTIC DRUGS CLASS Pharmacy and Therapeutics (P & T) and Formulary Committees to provide ALTERNATIVES physicians and pharmacists with a method to evaluate the safety, efficacy and cost- clindamycin/tretinoin, ACNE AGENTS, effectiveness of commercially available drug products. A structured approach to the VELTIN drug selection process is essential in ensuring continuing patient access to rational ZIANA TOPICAL drug therapies. The ultimate goal of the MedPerform Formulary is to provide a morphine sulfate ER process and framework to support the dynamic evolution of this document to guide tablets, oxycodone ANALGESICS, KADIAN prescribing decisions that reflect the most current clinical consensus associated ER, NUCYNTA, NARCOTICS with drug therapy decisions. NUCYNTA ER ANALGESICS, This is accomplished through the auspices of the MedImpact P & T and Formulary BELBUCA BUTRANS PATCH Committees. These committees meet quarterly and more often as warranted to NARCOTICS ensure clinical relevancy of the Formulary. To accommodate changes to this ABSTRAL, document, updates are made accessible as necessary. FENTORA, fentanyl citrate ANALGESICS, LAZANDA, lozenge NARCOTICS As you use this Formulary, you are encouraged to review the information and ONSOLIS, provide your input and comments to the MedImpact P & T and Formulary SUBSYS Committees. immediate-release GRALISE ANTICONVULSANTS The MedImpact P & T
  • Comparison of Clinical Effects Between

    Comparison of Clinical Effects Between

    Kanno et al. Renal Replacement Therapy (2020) 6:7 https://doi.org/10.1186/s41100-019-0253-4 REVIEW Open Access Comparison of clinical effects between icodextrin and glucose solutions on outcomes of peritoneal dialysis: systematic review and meta-analysis of randomized controlled trials Atsuhiro Kanno1*, Yasushi Tsujimoto2, Takayuki Fujii3, Emi Fujikura4, Kimio Watanabe5, Hidemichi Yuasa6, Munekazu Ryuzaki7, Yasuhiko Ito8 and Hidetomo Nakamoto9 Abstract Background: Icodextrin enhances peritoneal filtration for patients on peritoneal dialysis (PD). However, clinically important outcomes have not yet been analyzed using authentic, objective statistical methods. The present systematic review aimed to determine the risks and benefits of icodextrin compared with a glucose-based solution with respect to clinically important and patient-centered outcomes. Methods: We systematically investigated only randomized controlled trials (RCTs) by adopting the Cochrane Database of Systematic Review (2014) and searched the CENTRAL, MEDLINE, and EMBASE databases for eligible studies reported in the literature. The quality of the evidence was assessed using the GRADE approach. Results: We finally evaluated important outcomes in 13 RCTs. Icodextrin significantly decreased the number of reported episodes of uncontrolled fluid overload in four RCTs that involved 236 patients (relative risk [RR], 0.31; 95% confidence interval [CI], 0.12 to 0.82; moderate certainty evidence). However, the inclusion of icodextrin for peritoneal ultrafiltration did not significantly differ in six RCTs involving 252 patients (mean difference [MD], 186.76 mL; 95% CI, − 47.08 to 420.59; low certainty evidence). Regarding other clinically important outcomes, all-cause mortality in 10 RCTs involving 1106 patients (RR, 0.75; 95% CI, 0.33 to 1.71; low certainty evidence) and technical survival in five RCTs involving 470 patients (RR, 0.57; 95%CI, 0.29 to 1.12; low certainty evidence) were not significant.
  • Printed Formulary Catalog Basic

    Printed Formulary Catalog Basic

    Scripps Health Formulary July 2016 Foreword Pharmacy and Therapeutics Committee. MedImpact approves such multi- This document represents the efforts of the MedImpact Healthcare Systems source drugs for addition to the MAC list based on the following criteria: Pharmacy and Therapeutics (P & T) and Formulary Committees to provide physicians A multi-source drug product manufactured by at least one (1) nationally and pharmacists with a method to evaluate the safety, efficacy and cost-effectiveness marketed company. of commercially available drug products. A structured approach to the drug selection At least one (1) of the generic manufacturer’s products must have an “A” process is essential in ensuring continuing patient access to rational drug therapies. rating or the generic product has been determined to be unassociated with The ultimate goal of the Portfolio Formulary is to provide a process and framework to efficacy, safety or bioequivalency concerns by the MedImpact P & T support the dynamic evolution of this document to guide prescribing decisions that Committee. reflect the most current clinical consensus associated with drug therapy decisions. Drug product will be approved for generic substitution by the MedImpact P & T Committee. This is accomplished through the auspices of the MedImpact P & T and Formulary Committees. These committees meet quarterly and more often as warranted to ensure This list is reviewed and updated periodically based on the clinical literature and clinical relevancy of the Formulary. To accommodate changes to this document, pharmacokinetic characteristics of currently available versions of these drug updates are made accessible as necessary. products. As you use this Formulary, you are encouraged to review the information and provide If a member or physician requests a brand name product in lieu of an approved your input and comments to the MedImpact P & T and Formulary Committees.
  • Malta Medicines List April 08

    Malta Medicines List April 08

    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
  • Index B Alphabetical List of Pharmaceutical Product Names

    Index B Alphabetical List of Pharmaceutical Product Names

    INDEX B ALPHABETICAL LIST OF PHARMACEUTICAL PRODUCT NAMES PRODUCT NAME Page PRODUCT NAME Page 292 97 ACYCLOVIR 17 3TC (EDS) 14 ACYCLOVIR 17 5-AMINOSALICYLIC ACID (MESALAMINE) 170 " 18 ABACAVIR SO4 13 ADALAT XL 57 ABACAVIR SO4/LAMIVUDINE 13 ADALIMUMAB 220 ABACAVIR SO4/LAMIVUDINE/ZIDOVUDINE 13 ADAPALENE 206 ABATACEPT 220 ADCIRCA (EDS) 89 ABILIFY (EDS) 123 ADEFOVIR DIPIVOXIL 18 ACARBOSE 187 ADHESIVE WIPES (EDS) 239 ACCEL PIOGLITAZONE (EDS) 190 ADVAGRAF (EDS) 231 ACCEL TOPIRAMATE 112 ADVAIR (EDS) 33 ACCEL-CITALOPRAM 114 ADVAIR DISKUS (EDS) 33 ACCOLATE (EDS) 232 AGGRENOX (EDS) 87 ACCU-CHEK 1 MINI (EDS) 238 AGRYLIN 221 ACCU-CHEK 2 MINI (EDS) 238 AIROMIR 32 ACCU-CHEK ADVANTAGE 142 ALCOHOL PREP 234 ACCU-CHEK AVIVA 142 ALCOHOL SWAB 234 ACCU-CHEK COMPACT 142 ALDACTAZIDE-25 82 ACCU-CHEK FASTCLIX MOBILE 234 ALDACTAZIDE-50 82 ACCU-CHEK LINKASSIST (EDS) 239 ALDACTONE 148 ACCU-CHEK MOBILE 142 ALDARA (EDS) 209 ACCU-CHEK MULTICLIX 234 ALENDRONATE (EDS) 220 ACCU-CHEK RAPID D (EDS) 236 ALENDRONATE SODIUM 220 " 237 ALENDRONATE SODIUM (EDS) 220 " 238 ALENDRONATE SODIUM/VITAMIN D3 ACCU-CHEK SPIRIT (EDS) 236 (CHOLECALCIFEROL) 220 ACCU-CHEK TENDER 1 (EDS) 238 ALERTEC (EDS) 133 " 239 ALESSE 181 ACCU-CHEK TENDER 2 (EDS) 238 ALFACALCIDOL 217 " 239 ALFUZOSIN 220 ACCU-CHEK ULTRAFLEX 1 (EDS) 237 ALGLUCOSIDASE ALFA 221 " 238 ALLOPURINOL 221 ACCU-CHEK ULTRAFLEX 2 (EDS) 237 ALMOTRIPTAN MALATE 33 " 238 ALOMIDE 158 ACCUPRIL 79 ALPHAGAN 157 ACCURETIC 80 ALPHAGAN P 157 ACCUTANE 209 ALPRAZOLAM 134 ACCUTREND 142 ALPRAZOLAM 134 ACEBUTOLOL 48 ALTACE 80 ACEBUTOLOL HCL 48 " 81
  • Pharmacokinetics of Ophthalmic Corticosteroids

    Pharmacokinetics of Ophthalmic Corticosteroids

    British Journal ofOphthalmology 1992; 76: 681-684 681 MINI REVIEW Br J Ophthalmol: first published as 10.1136/bjo.76.11.681 on 1 November 1992. Downloaded from Pharmacokinetics of ophthalmic corticosteroids Corticosteroids have been used by ophthalmologists with an identical vehicle, the aqueous humour concentrations of increasing frequency over the past 30 years, with the these steroids are almost identical.'9 None the less it is concomitant development of a diverse range of drop, essential when considering such empirical data, to recall that ointment, subconjunctival, and oral preparations. Though the systemic anti-inflammatory effect of both betamethasone the clinical benefits and side effects of such corticosteroid and dexamethasone is five to seven times that of predniso- preparations have been well documented, their basic lone.39"' The local anti-inflammatory potency of ocular pharmacokinetics in the human eye have yet to be fully steroids has yet to be fully investigated and whilst early work established. Indeed most of our pharmacokinetic knowledge suggested that prednisolone acetate 1% had the greatest anti- of these drugs has been elucidated by extrapolation of data inflammatory effect in experimental keratitis,'7 later studies obtained from rabbit experiments.1-26 These results can be demonstrated that fluorometholone acetate in a 1% formu- significantly disparate from human data because of the lation was equally efficacious in the same model.26 However, thinner rabbit cornea, lower rabbit blink rate, effect of prednisolone
  • Fluid and Pharmacological Agents for Adhesion Prevention After Gynaecological Surgery (Review)

    Fluid and Pharmacological Agents for Adhesion Prevention After Gynaecological Surgery (Review)

    Fluid and pharmacological agents for adhesion prevention after gynaecological surgery (Review) Ahmad G, Mackie FL, Iles DA, O’Flynn H, Dias S, Metwally M, Watson A This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2014, Issue 7 http://www.thecochranelibrary.com Fluid and pharmacological agents for adhesion prevention after gynaecological surgery (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 6 OBJECTIVES ..................................... 7 METHODS ...................................... 7 RESULTS....................................... 9 Figure1. ..................................... 10 Figure2. ..................................... 12 Figure3. ..................................... 13 Figure4. ..................................... 14 Figure5. ..................................... 15 Figure6. ..................................... 16 Figure7. ..................................... 17 Figure8. ..................................... 18 Figure9. ..................................... 18 Figure10. ..................................... 19 ADDITIONALSUMMARYOFFINDINGS . 22 DISCUSSION ..................................... 32 AUTHORS’CONCLUSIONS . 33 ACKNOWLEDGEMENTS . 33 REFERENCES ....................................
  • Teva Pharmaceutical Industries Ltd

    Teva Pharmaceutical Industries Ltd

    m n a d v s g o PRODUCT v1 2015 CATALOGUE h p b e q f i t w c l r z www.tapi.com PRODUCT CATALOGUE v1 2015 US CEP EU Japan Korea DMF DMF DMF DMF ABIRATERONE a ACYCLOVIR x x x AFATINIB ALCLOMETASONE DIPROPIONATE x x ALENDRONATE SODIUM x x x ALLOPURINOL x x x x AMCINONIDE x x x AMITRIPTYLINE HCL x x x x x AMLODIPINE BESYLATE x x x ANASTROZOLE x x x ANIDULAFUNGIN APIXABAN APREMILAST ARIPIPRAZOLE x x ARIPIPRAZOLE LAUROXIL ATORVASTATIN CALCIUM* x x x x ATOSIBAN ACETATE ATRACURIUM BESYLATE x x x AZACITIDINE x x AZITHROMYCIN x x x x AZTREONAM x BECLOMETHASONE DIPROPIONATE x x x x b BETAMETHASONE ACETATE x x x BETAMETHASONE BASE x x x BETAMETHASONE DIPROPIONATE x x x x BETAMETHASONE VALERATE x x x x BICALUTAMIDE x x BIMATOPROST x x BIVALIRUDIN x x BLEOMYCIN SULFATE x x BORTEZOMIB x x x * TAPI can provide several different polymorphs or processes of this product. To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager. For the most updated product list please go to "Products" at www.tapi.com Additional DMFs or Tech Files are available upon request All subject to the disclaimer on page 15 PRODUCT CATALOGUE v1 2015 US CEP EU Japan Korea DMF DMF DMF DMF BROMOCRIPTINE MESYLATE x x b BUDESONIDE x x x x BUPRENORPHINE BASE x x BUPRENORPHINE HCL x x x BUTORPHANOL TARTRATE x x CABAZITAXEL x CABERGOLINE x x x x c CALCIPOTRIENE (CALCIPOTRIOL)* x x x CALCITRIOL x x x CANDESARTAN CILEXETIL x CAPECITABINE x x CARBIDOPA x x x x CARBOPLATIN x x x x CARFILZOMIB CARVEDILOL BASE x x x x x CARVEDILOL PHOSPHATE x CASPOFUNGIN ACETATE x x CERITINIB CHLORMADINONE ACETATE x x CICLOSPORIN x x x x x CILOSTAZOL x x x x CINACALCET HCL x x CISATRACURIUM BESYLATE x x CISPLATIN x x x CLARITHROMYCIN x x x x x CLOBETASOL PROPIONATE x x x x x CLONAZEPAM x CLOPIDOGREL BISULFATE x x x x CYPROTERONE ACETATE x x d DABIGATRAN ETEXILATE x DARIFENACIN HBR x x * TAPI can provide several different polymorphs or processes of this product.